Dimethyl fumarate 240mg gastro-resistant capsules
NHS hospitals in England used £99,553,998 of indicative cost of Dimethyl fumarate 240mg gastro-resistant capsules in the 12 months to April 2026, about 0.4% of all hospital medicines spend. That is down 4.0% on the previous 12 months.
Indicative cost · 12 months
Quantity (VMP units) · 12 months
Share of hospital medicines spend
Figure 1. Dimethyl fumarate 240mg gastro-resistant capsules: NHS hospital indicative cost by month (£ millions)
Source: NHSBSA Secondary Care Medicines Data, to April 2026
Cost is indicative — actual hospital medicine prices are commercially confidential, so these figures are estimated from list prices. See methodology.
NHS trusts using Dimethyl fumarate 240mg gastro-resistant capsules most
By indicative cost over the 12 months to April 2026.
| NHS trust | Indicative cost (12 months) |
|---|---|
| University College London Foundation Tr | £4,934,712 |
| Sheffield Teaching Hospitals Nhs Trust | £4,369,818 |
| University Hospital Southampton Nhs Ft | £4,047,701 |
| The Walton Centre Nhs Foundation Trust | £3,928,515 |
| Leeds Teaching Hpls Nhs Trust | £3,890,429 |
| Salford Royal Nhs Foundation Trust | £3,845,043 |
| Cambridge Univ Hosp Nhs Foundation Trust | £3,557,274 |
| Nottingham University Hospitals Trust | £3,110,110 |
| University Hpls Of Leicester Nhs Trust | £2,857,003 |
| Imperial College Healthcare Nhs Trust | £2,786,887 |
The primary-care picture
No confident match to a community-dispensed medicine was found for this product, so no primary-care comparison is shown. SCMD products are recorded at product level, which does not always map cleanly to a BNF substance.